Pregnancy and Lactation Outcomes in a Turkish Patient with Lysinuric Protein Intolerance

Abstract

Maternal lysinuric protein intolerance (LPI) is associated with increased risk of anemia, toxemia, and retarded growth in fetus during pregnancy, and bleeding complications during delivery. There has been limited number of reports about pregnancy and outcomes of lactation in LPI. Here we present pregnancy and lactation outcomes in a Turkish patient with LPI. In the pregnancy and delivery period, her metabolic status was stable with protein-restricted diet and citrulline. Pathological examination of the placenta revealed multifocal placental infarcts. A successful outcome was achieved with well-controlled anemia, thrombocytopenia despite hemophagocytosis in bone marrow, and placental infarcts during pregnancy. The baby was exclusively breastfed for 6 months. His growth and development was normal. Mild proteinuria started at the fourth month of the delivery. Our case report showed the importance of follow-up of these patients in terms of placental pathologies during pregnancy and for other complications during lactation period.

Competing interests: None declared

Appendices

Take-Home Message

Follow-up of the patients with lysinuric protein intolerance is important in terms of placental pathologies during pregnancy and for other known complications of the disease during lactation period.

Compliance with Ethical Guidelines

• The article has not been and will not be published elsewhere in the same form (Accepted as a poster presentation at ICIEM 2013).

• The submitting author has circulated the article and secured final approval of the version to be peer-reviewed from all coauthors prior to the publication of the article.

• Substantial contribution of coauthors to the work: The report was planned by first, second, and last authors; pathological investigations were performed by third author; obstetrical follow-up of the patient was performed by seventh author. All authors contributed to the conception and interpretation of data. First draft was written by the first author and revised by the second author.

• Özlem Ünal, Turgay Coşkun, Diclehan Orhan, Ayşegül Tokatlı, Ali Dursun, Burcu Hişmi, Özgür Özyüncü, and Serap Hatice Kalkanoğlu Sivri declare that they have no conflict of interest.

• All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5).

• Informed consent was obtained from the patient for publication.

• This article does not contain any studies with human subjects performed by the any of the authors.